Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders characterized by refractory cytopenias and susceptibility to leukemic transformation. On a subset of MDS patients with deletion of the long arm of chromosome5 (del(5q)), lenalidomide exerts hematological and cytogenetic effects, but the underlying pharmacological mechanisms are not fully understood. In this study, we have investigated the in vitro effects of lenalidomide on an MDS-derived cell line, MDS-L, which carries del(5q) and complex chromosome abnormalities. We found that the growth of MDS-L cells was specifically suppressed mainly by apoptosis, and in addition, multinucleated cells were frequently formed and finally died out in the presence of lenalidomide. Time-lapse microscopic observation and the DNA ploidy analysis revealed that lenalidomide does not affect DNA synthesis but inhibits cytokinesis of MDS-L cells. The gene expression profile showed decreased expression of M phase-related genes such as non-muscle myosin heavy-chain 10, polo-like kinase 1, aurora kinase B, citron kinase and kinesin family member 20A(KIF20A). Interestingly, KIF20A is located at 5q31. These data contribute to the understanding of action mechanisms of lenalidomide on MDS with del(5q) and complex abnormalities.
Introduction
The myelodysplastic syndromes (MDS) are a group of hematological disorders as a result of clonal growth of pathological stem cells and ineffective hematopoiesis. 1 Chromosomal abnormalities in marrow cells are found in 40-60% of MDS patients, and deletion of chromosome 5q (del(5q) /5q-) occupies 10-20% of the abnormalities. 2 Van den Berghe et al. reported a subtype of refractory macrocytic anemia characterized by isolated del(5q), normal or elevated platelet counts, abnormal hypolobated megakaryocytes and rare progression to acute myeloid leukemia. 3 This '5q-syndrome' is described as an independent clinical entity in the World Health Organization classification of MDS. 4 Although the deleted area of 5q is different in case by case, del(5)(q32q33) is considered as a common deleted region. 5, 6 The common deleted region expected in patients with 5q-syndrome is located distal to the region recognized in higher-risk groups with del(5q) that are susceptible to leukemic transformation. 6 Several hematopoiesis-related genes and tumor suppressor genes are located at 5q locus, and SPARC, 7 
CTNNA1,
8 EGR1, 9 RPS14 10 and CDC25C 11 are reported as the candidate genes of MDS with del(5q) or 5q-syndrome.
Lenalidomide, a derivative of thalidomide, is shown to exert plenty of biological actions including inhibition of angiogenesis, 12 suppression of proinflammatory cytokine production such as TNF-a, 13 enhancement of T-and NK-cell activation. [14] [15] [16] Lenalidomide also brings about the improvement of erythropoiesis on MDS patients with del(5q) and in addition it is capable of eradicating the abnormal del(5q) clone. 17 Hence this drug has been paid attention as a specific therapeutic agent for MDS with del(5q). It is reported that lenalidomide inhibits the growth of CD34-positive cells having del(5q) 7 or Burkitt lymphoma cell lines 18 and that SPARC is upregulated by lenalidomide treatment, 7 but at present the target gene(s) of lenalidomide and its underlying action mechanisms are not determined yet.
In this study, we investigated the in vitro effects of lenalidomide on MDS-L, a myelodysplastic cell line with del(5q) and complex karyotypic abnormalities and searched the growth inhibition mechanism by lenalidomide.
Materials and methods

Reagents
Lenalidomide, generously provided by Celgene Corporation (Warren, NJ, USA) was dissolved in dimethylsulfoxide (DMSO) and stored at À20 1C. After thawing the stock solution it was protected from light and kept at 4 1C. According to the reported in vitro studies, 7, 18, 19 we used 10 mM lenalidomide and the final DMSO concentration was 0.01%.
Cell lines and culture
A human myeloblastic cell line, MDS-L 20 was derived as a subline from a myelodysplastic cell line, MDS92 which was established from the bone marrow of an MDS patient with del(5q). 21, 22 MDS-L cells were positive for CD34, c-Kit, HLA-DR, CD13, CD33 and partially positive for CD41 and negative for CD3, CD14, CD20 and glycophorinA. The main karyotype was 49, XY, þ 1, der(5)t(5;19), À7, þ 8, À12, der(13)t(7;13), der(14)t (12;14) , der(15)t(15;15), þ 19, þ 20, þ 21, der(22)t (11;22) . Multicolor fluorescence in situ hybridization analysis indicated that MDS-L does not show a simple deletion of the single 5q locus but reveals a derivative small chromosome5 as a result of t(5;19)(q11;q13). Fluorescence in situ hybridization analysis targeting the 5q locus also indicated that the distal portion from 5q11.1 was certainly lost. MDS-L cells were maintained in RPMI1640 medium supplemented with 10% fetal bovine serum, 50 mM 2-mercaptoethanol, 2.0 mM L-glutamine and 100 U/ml IL-3. Lenalidomide (10 mM) or 0.01% DMSO were added daily during the experiments. Human myeloid leukemia cell lines carrying del(5q), HL-60 and KG-1 were also used. Cell growth was assessed by counting the number of living cells. The morphological assessment was performed with May-Gruenwald-Giemsa stained cytospin slides.
Apoptosis assay
The apoptosis was examined using AnnexinV Apoptosis Detection Kit (BD Pharmingen, San Diego, CA, USA) and all samples were analyzed by FACS Calibur flow cytometer and CellQuest software(Becton Dickinson, Franklin Lakes, NJ, USA).
Immunofluorescence study MDS-L cells were centrifuged onto cytospin slides and fixed for 30 s in 4% formalin/50% acetone, then permeabilized with lysis buffer including 0.2% Triton X-100, 25 mM HEPES, 60 mM PIPES, 10 mM EGTA and 2 mM MgCl 2 for 30 s. Antibody staining was performed using mouse monoclonal anti-aurora kinase A (BD biosciences, San Jose, CA, USA), rabbit polyclonal anti-CDC25C(Santa Cruz Biotechnology, Santa Cruz, CA, USA) to detect centrosomes, 23 and AlexaFluor488-or AlexaFluor594-conjugated anti-IgG antibodies (Molecular Probes, Eugene, OR, USA) as secondary antibodies. The nucleus was stained with DAPI (Dojindo, Kumamoto, Japan). Cells were observed under an Olympus BX51 fluorescence microscope and a Â 100/1.35 numerical aperture oil objective.
Live cell imaging by a time-lapse microscopy Cells were seeded in 35 mm glass bottom culture dish and then 100 ng/ml Hoechst 33342 Dojindo was added for 1 h. Time-lapse imaging was performed on Zeiss Axiovert 200 M microscope (Zeiss, Gö ttingen, Germany) equipped with halogen light source, xenon lump, C4742-95ER digital camera and the Aquacosmos/ratio imaging system (Hamamatsu photonics K.K., Hamamatsu, Japan) at 37 1C and 5% CO 2 . All images were collected using Zeiss Ph2 plan-NEOFLUAR Â 40, 0.75 numerical aperture objective. Camera binning was 2 Â 2, imaging times were 240 ms. Each image was captured every 2 min until the time points as indicated.
Cell-cycle and DNA ploidy analyses
Cells were fixed with 100% methanol for 60 min and treated with 2 mg/ml ribonuclease A (Nacalai Tesque, Kyoto, Japan) for 20 min at 37 1C, next with 50 mg/ml propidium iodide (PI; Sigma, St Louis, MO, USA) for further 20 min at room temperature. As to the analysis using bromodeoxyuridine (BrdU) and 7-amino-actinomycinD (7-AAD), the cells were pulselabeled with 10 mM BrdU for 120 min and the cell-cycle assay was performed using BrdU Flow Kit (BD Pharmingen) and FACS Calibur flow cytometer. DNA ploidy was analyzed by the use of a laser-scanning cytometry as previously described. 24 Briefly, the cytospin samples stained with May-Gruenwald-Giemsa were captured with a CCD camera and their coordinates (x and y) on the slide were recorded. Next the identical smears were treated with 2 mg/ml ribonuclease A for 1 h at 37 1C and restained with 100 mg/ml PI, and the fluorescence intensity of each cell was quantified as the DNA contents together with the morphological assessment.
Statistical analyses
To compare the two nuclei of binucleated cells, we measured the surface area and DNA ploidy of each nucleus and calculated the Pearson product-moment correlation coefficients and the Sperman rank correlation coefficients.
Gene expression profiling
Gene expression profiling of MDS-L cells was examined in three independent experiments (lenalidomide-treated or DMSO-treated cells were harvested once on day 7 and twice on day 9). Total RNA was extracted with RNeasy Mini Kit (Qiagen, Germantown, MD, USA) and 5 mg of total RNA was amplified with the one-cycle cDNA synthesis and the one-cycle Target Labeling and Control Reagent packages (Affymetrix Santa Clara, CA, USA). Biotin-labeled fragmented cDNA was hybridized to Affymetrix-GeneChip Human Genome U133 Plus 2.0 Arrays covering 447,000 transcripts representing 39,000 human genes. Chips were washed and scanned with a GeneChip Scanner 3000 (Affymetrix).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted with RNeasy Mini Kit (Qiagen) and RT-PCR was performed using One step RNA PCR Kit (TAKARA BIO, Otsu, Japan) and following primers: non-muscle myosin heavy-chain10(MYH10) (sense:CATCTACAACCCTGCCACTC; antisense:TCCTCACGATCTTGAAGCATG), aurora kinase B(AURKB) (sense:ATGGCCCAGAAGGAGAACTC; antisense:TTCTCCCG AGCCAAGTACAC), polo like kinase (sense:ATGAGTGCTGCA GTGACTGC; antisense:GAGCAGCAGAGACYYAGGCA), kinesin family member 20A (KIF20A)(sense:CTAAATTACAGCAGTG CAAAGCAG; antisense:TTAGTACTTTTTGCCAAAAGGCCCAG), CDC14A(sense:CTCCATCGATGAGGAGCTGG; antisense:GAC AGGAGTGCTCTGTAGGC), SPARC (sense:CTGTGGCAGAGGT GACTGAG; antisense:GGCAGGAAGAGTCGAAGGTC), glyceraldehydes-3-phosphate dehydrogenase (GAPDH) (sense:GCC TCCTGCACCACCAACTG; antisense:CCCTCCGACGCCTGCTT CAC). PCR was performed using GeneAmp PCR system 9700 (Applied Biosystems, Tokyo, Japan) for 30 cycles, each consisting of 30 s at 94 1C, 30 s at 58 1C and 30 s at 72 1C.
Immunoblotting analysis
Cell lysates of MDS-L were prepared in lysis buffer containing 50 mM Tris-HCL, 150 mM NaCl, 5 mM EDTA, 0.5% TritonX-100, 0.05% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate, 2 mM phenylmethylsulfonyl fluoride and 1 mM Na3VO4. Cell lysates were separated in SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting analysis was performed as previously described. 25 Used primary antibodies were rabbit anti-KIF20A(Bethyl Laboratories, Montgomery, TX, USA) and mouse anti-aurora kinase B(BD Biosciences, San Jose, CA, USA).
Results
Treatment with lenalidomide inhibits the proliferation of MDS-L cell line
As lenalidomide is reported to inhibit the growth of CD34-positive cells with del(5q) 7 or Burkitt lymphoma cell lines, 18 we investigated the effect of lenalidomide on the growth of myeloid cell lines carrying del(5q). Daily addition of lenalidomide to in vitro culture did not show any suppressive effect on HL-60
Effects of lenalidomide on a 5q-MDS cell line A Matsuoka et al (Figure 1a ) nor KG-1 (data not shown). In contrast, MDS-L cells proliferated in the presence of IL-3 by day 4, but after that the cell number was gradually decreased together with appearance of dying or dead cells (Figures 1a and 2a) . We analyzed apoptosis by dual staining of annexinV and PI, and found that lenalidomide induces apoptotic cell death onto a major part of MDS-L cells after around day 5 ( Figure 1b) .
MDS-L cells become multinucleated and polyploid by the treatment with lenalidomide
Lenalidomide-induced apoptosis to most of MDS-L cells, and we also found that lenalidomide treatment brought about the appearance of binucleated cells on day 4 (before the beginning of massive cell death) and subsequently multinucleated cells were often detected. On day 10 about a half of the cells which survived under lenalidomide treatment represented multinuclearity (Figures 2a and b) .
In general, cell division consists of the two-step process: nuclear division (mitotic division) and subsequent cytoplasmic division (cytokinesis). Disturbance of either division might give rise to multinucleated cells. To examine whether the chromosome segregation ordinarily occurs or not, we compared the size and DNA contents of two nuclei of more than 100 binucleated cells by photomicrographic measurement and laser-scanning cytometry, respectively, and confirmed that the two nuclei were almost of the same size (the correlation coefficient between the two nuclei was 0.827) and such cells proved to be certainly 4N. These data indicate that lenalidomide treatment does not impair the DNA synthesis and that the chromosome segregation is normally accomplished to generate equally binucleated cells.
Next, we analyzed the cell-cycle pattern and the DNA ploidy of lenalidomide-treated MDS-L cells by flow cytometry. The percentage of subdiploid (o2N) cells was increased and instead diploid (2N) cells were decreased after lenalidomide treatment (Figure 3a) . Furthermore, the cells with polyploidy such as tetraploid (4N) on day 4, and subsequently hyperpolyploid cells Effects of lenalidomide on a 5q-MDS cell line A Matsuoka et al such as 8N and 16N were detected. Together with morphological finding, it was suggested that some parts of 4N cells entered the cell cycle again and formed hyperploid cells. The BrdU and 7-AAD dual-staining assay indicated that lenalidomide hardly inhibited DNA synthesis and a small part of the cells entered the next cell cycle from 4N to 8N to generate polyploid cells (Figure 3b ). Taken together, a small part of the cells entered the next cell cycle to form multinucleated cells and finally they also died out.
Treatment with lenalidomide inhibits cytokinesis of MDS-L cells
As described above, lenalidomide treatment caused the increase in binucleated cells, but seemed not to affect DNA synthesis or mitotic division. Hence, we speculated that one of the direct action of lenalidomide is inhibition of cytokinesis. We observed lenalidomide-treated or control MDS-L cells by a time-lapse microscopy and chased the whole process of cell division. The control cells showed normal mitosis and cytokinesis and gave Effects of lenalidomide on a 5q-MDS cell line A Matsuoka et al rise to two daughter cells in more than 90% of observed cell division examples. In lenalidomide-treated cells, on the contrary, the cleavage furrow was formed after mitosis and the cells were about to divide into two daughter cells, but the cytokinesis was interrupted. The furrow became widened and finally binucleated cells were formed (Figure 4a ). Such an aborted cytokinesis was ubiquitously detected by daily addition of lenalidomide, resulting in frequent appearance of multinucleated cells (Figure 4b, Figures 2a and b) .
Treatment with lenalidomide suppresses the gene expression of M phase-related molecules in MDS-L cells
We harvested lenalidomide-treated or control MDS-L cells once on day 7 and twice on day 9, and investigated the gene expression profiling. The three independent studies represented almost the same pattern of gene expression profiles, and lenalidomide treatment resulted in the decreased gene expression of M phase-related molecules (Supplementary Table 1 ). Among them, the expression of MYH10, aurora kinase B, PLK1, CDC14A and citron kinase was particularly declined and these changes were also confirmed by RT-PCR (Figure 5a ) and in part by immunoblotting analysis (data not shown).
As for the genes located at 5q, after lenalidomide treatment, the expression of interferon regulatory factor 1 (IRF1) and KIF20A was decreased to 0.43-fold (range: 0.34-0.49) and 0.41-fold (range: 0.05-0.65), respectively. Inversely, the expression of early growth response 1 (EGR1), colony-stimulating factor 1   100min 120min 140min 144min 154min  50min  80min 112min 118min 128min   18min  12min  30min  50min  80min  24min  20min  28min  32min  36min   0min  2min  4min  6min  8min  0min  4min  8min  12min  16min   0%   20%   40%   60%   80%   100%   control day1  day2  day3  day4 abnormal cytokinesis normal cytokinesis Effects of lenalidomide on a 5q-MDS cell line A Matsuoka et al (CSF-1R) and endothelial cell-specific molecule 2 (ECSM2) was increased to 11.5-fold (range: 4.7-26.5), 16.2-fold (range: 7.7-21.7) and 37.4-fold (range: 16.9-56.8), respectively. Expression of SPARC was rather weak or absent and not enhanced after lenalidomide treatment by RT-PCR (Figure 5b ) and the gene expression profiling (data not shown).
Lenalidomide induces aberrant multiplication of centrosomes in MDS-L cells
We showed that lenalidomide induces cell death in part by formation of multinucleated cells by inhibition of cytokinesis.
We also indicated that a part of polyploidy cells enter the next cell cycle (Figures 3a and b) . Nigg 26 reported that the cells presenting aberrant centrosome number form multipolar spindle in the next M phase and are not able to survive because of a lack of essential genes. In fact, the mitotic cells with multiple centrosomes were observed frequently on day 4 after lenalidomide treatment in MDS-L cells (Figures 6a and b) . These data suggested that aberrant multiplication of centrosomes caused by cytokinesis failure is one mechanism of lenalidomide-induced cell death.
Discussion
There are important genes encoding or involved in tumor suppression, growth factors and their receptors, transcriptional factors at 5q locus, and certain genes might also be related to lenalidomide-specific growth suppression. In this study, we performed in vitro studies using MDS-L cell line which had been established from an MDS patient with del(5q) to further investigate del(5q)-related leukemogenesis and action mechanisms of lenalidomide.
MDS-L cell line carries a derivative small chromosome5 as a result of t(5;19)(q11;q13) and complex abnormalities instead of simple del(5q). Hence, this cell line should not be called as a typical 5q-cell line. However, an intensive study by Drexler et al. 22 confirmed that MDS92 (a parental cell line of MDS-L and carries the similar chromosome abnormalities including 5q change) shows the loss of BAC RP11-54C4 signal indicating 5q31-32 deletion. Therefore, MDS-L will be one of the available cell models with del(5q). Both HL-60 and KG-1 cell lines also represent del(5q) but neither of them showed growth suppression nor multinuclearity by lenalidomide treatment (data not shown). The effects of lenalidomide seem to be exerted exclusively on MDS-L cells.
Gandhi et al. 18 reported that lenalidomide shows an inhibitory effect on Namalwa cells by inducing G0/G1 arrest. Pellagatti et al. 7 reported that lenalidomide suppresses the growth of CD34-positive cells derived from the MDS with del(5q) and brings about the enhanced expression of SPARC. As for MDS-L, on the contrary, lenalidomide did not promote the expression of SPARC (Figure 5b In this study, we showed that lenalidomide treatment induces multinuclearity by inhibition of cytokinesis in MDS-L cells (Figure 4 ). To date, several studies have indicated that the contractile ring which forms cell cleavage furrow involves various intracellular molecules: Rho-pathway molecules such as Rho GTPase, Rho kinase, citron kinase and formin; mitotic kinases, such as aurora kinase B and PLK1; molecules located on the central spindles, such as kinesin-like motors (MKLP1, MKLP2), ECT2 and MgcRacGAP. 26 Suppression of these molecules results in the formation of binucleated cells. 27, 28 To approach the inhibitory mechanism of lenalidomide on cytokinesis of MDS-L cells, we inspected the gene expression profiles by microarray analysis and found decreased expression of M phase-related genes including cytokinesis-related molecules (Supplementary Table 1) .
KIF20A (Rab6KIFL/MKLP2) is a kinesin-like protein, interacts with Rab6 that is associated with vesicular transport and has an important role in cytokinesis. 29, 30 Interestingly, KIF20A is located at 5q31 and its expression was inhibited by lenalidomide treatment (Figure 5a ). These results raise the possibility that KIF20A is one of the target genes of lenalidomide. It is also Effects of lenalidomide on a 5q-MDS cell line A Matsuoka et al reported that KIF20A associates with aurora kinase B and CDC14A phosphatase 31 and inhibition of CDC14A expression by siRNA method leads to the appearance of binucleated cells. 32 Myosin II is known to be involved in cytokinesis, and in our study the expression of MYH10 was decreased by treatment of MDS-L with lenalidomide (Figure 5a ), suggesting its relation to the inhibition of cytokinesis.
The cells which failed in cytokinesis bear multiple nuclei, and consequent multiplication of centrosomes causes impaired chromosomal segregation at the coming M phase and might result in mitotic cell death. 26, 33 In fact, lenalidomide-treated MDS-L cells formed binucleated cells with four centrosomes around day 4 and then the cells with multiplicate centrosomes increased (Figure 6a) . Such multinucleated cells with multiplicated centrosomes finally fall into cell death probably as a result of death induction by tetraploid checkpoint mechanism as reported by Andreassen. 34 In our study, treatment of MDS-L cells with lenalidomide induces multinucleated cells, which are destined to die, and KIF20A located at 5q31 locus is proposed as a possible candidate target gene of lenalidomide. This investigation will contribute to molecular study of the myeloid malignancies with del(5q) and therapeutic mechanisms of lenalidomide. However, as MDS-L cells carry complex chromosome abnormalities besides the 5q change, the effects of lenalidomide on MDS-L might be attributable to some of the multiple genetic alterations.
The prognosis of MDS patients with del(5q) depends on various factors including additional chromosome abnormalities, [35] [36] [37] but lenalidomide exerts a favorable effect on 5q-MDS patients with complex abnormalities similarly as the patients with isolated del(5q) or to a lesser degree. 35, 38, 39 Our basic study might provide potentially useful issues to explain the clinical efficacy of lenalidomide on the patients with del(5q) and additional abnormalities.
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